Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Molecular Diagnostics dealmaking

 

2.1. Introduction

2.2. Molecular Diagnostics partnering over the years

2.3. Most active Molecular Diagnostics dealmakers

2.4. Molecular Diagnostics partnering by deal type

2.5. Molecular Diagnostics partnering by therapy area

2.6. Deal terms for Molecular Diagnostics partnering

2.6.1 Molecular Diagnostics partnering headline values

2.6.2 Molecular Diagnostics deal upfront payments7

2.6.3 Molecular Diagnostics deal milestone payments

2.6.4 Molecular Diagnostics royalty rates

 

Chapter 3 – Leading Molecular Diagnostics deals

 

3.1. Introduction

3.2. Top Molecular Diagnostics deals by value

 

Chapter 4 – Most active Molecular Diagnostics dealmakers

 

4.1. Introduction

4.2. Most active Molecular Diagnostics dealmakers

4.3. Most active Molecular Diagnostics partnering company profiles

 

Chapter 5 – Molecular Diagnostics contracts dealmaking directory

 

5.1. Introduction

5.2. Molecular Diagnostics contracts dealmaking directory

 

Chapter 6 – Molecular Diagnostics dealmaking by technology type

 

Chapter 7 – Partnering resource center

 

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

 

Appendices

 

Appendix 1 – Molecular Diagnostics deals by company A-Z

 

Appendix 2 – Molecular Diagnostics deals by stage of development

 

Discovery

Preclinical

Phase I

Phase II

Phase III

Regulatory

Marketed

Formulation

 

Appendix 3 – Molecular Diagnostics deals by deal type

 

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Evaluation        

Grant

Joint venture

Licensing

Litigation

Manufacturing

Marketing

Material transfer

Option

Promotion

Research

Settlement

Spin out

Sub-license

Supply

Technology transfer

Termination

Warranty

 

Appendix 4 – Molecular Diagnostics deals by therapy area

 

Appendix 5 –Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Molecular Diagnostics partnering since 2010

Figure 2: Active Molecular Diagnostics dealmaking activity– 2010 to 2018

Figure 3: Molecular Diagnostics partnering by deal type since 2010

Figure 4: Molecular Diagnostics partnering by disease type since 2010

Figure 5: Molecular Diagnostics deals with a headline value

Figure 6: Molecular Diagnostics deals with an upfront value

Figure 7: Molecular Diagnostics deals with a milestone value

Figure 8: Molecular Diagnostics deals with a royalty rate value

Figure 9: Top Molecular Diagnostics deals by value since 2010

Figure 10: Most active Molecular Diagnostics dealmakers 2010 to 2018

Figure 11: Online partnering resources

Figure 12: Forthcoming partnering events